immunity News and Research

RSS

Daily circadian cycles may impact our ability to fight disease

An analysis of an exhaustive dataset on cells essential to the mammalian immune system shows that our ability to fight disease may rely more heavily on daily circadian cycles than previously assumed.

12 Jan 2021

Scientists determine ideal dose of stem cells to control HIV

Scientists have determined the optimal conditions following a stem cell transplant that could control HIV without the need of an everyday pill, according to a study published today in eLife.

12 Jan 2021

UTSW study uncovers a gene linked to growth of breast cancer

A team of UT Southwestern researchers has identified a gene involved in the growth of breast cancer, a finding that could lead to potential new targets for treatment.

12 Jan 2021

Could Vitamin D be an effective adjuvant to help mitigate the COVID-19 pandemic?

As the coronavirus pandemic continues to wreak havoc across the globe, there is a dire need for effective and safe therapeutics and vaccines. Overall, the pandemic has infected more than 90.87 million people and taken more 1.94 million lives.

12 Jan 2021

SARS-CoV-2 exposure in England could be double reported seroprevalence

A new study that recently appeared on the preprint server medRxiv* makes use of a combined method to estimate population exposure to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), taking into account the fact that patients who recover from the infection often do not have circulating antibodies against the virus.

11 Jan 2021

The mystery of Giglio island’s resistance to COVID-19

An intriguing new study explores the mechanisms by which an Italian island called Giglio remained resistant to coronavirus disease 2019 (COVID-19) even after much exposure.

11 Jan 2021

Study supports continuing phase 3 trials of Ad26.COV2.S SARS-CoV-2 vaccine

An international team of researchers has provided further evidence to confirm the immunogenicity and efficacy of a recombinant adenovirus vaccine currently being tested in phase 3 trials for its ability to protect against infection with severe acute respiratory coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

11 Jan 2021

Sustained immune response memory detected in recovered COVID-19 patients

A team of researchers at the University of Washington School of Medicine has found that people who had mild COVID-19 developed a multi-layered immune response against SARS-Cov-2. The researchers detected neutralizing antibodies against the virus for at least three months after recovering from the infection.

11 Jan 2021

Single-dose nanoparticle vaccine for SARS-CoV-2

Before the pandemic, the lab of Stanford University biochemist Peter S. Kim focused on developing vaccines for HIV, Ebola and pandemic influenza.

8 Jan 2021

How do SARS-CoV-2 antibodies change over time in recovered patients?

Researchers studied convalescent plasma from recovered coronavirus disease 2019 (COVID-19) patients, with samples collected up to 34 weeks after recovery. They found IgG antibodies gradually declined with a median half-life of about 60 days.

8 Jan 2021

Link between fever, diarrhea, severe COVID-19, and persistent anti-SARS-CoV-2 antibodies

A new preprint research paper appearing on the medRxiv server describes a link between the persistence of neutralizing antibodies against the virus, disease severity, and specific COVID-19 symptoms.

7 Jan 2021

Potential role of chitinase 3-like-1 in severity of COVID-19

Now, an intriguing preprint research paper on the bioRxiv server reports the identification of an enzyme called chitinase 3-like-1 (CHI3L1) that mediates this age-dependent impact of the virus and could serve as a powerful therapeutic approach in mitigating the severity of COVID-19 in this high-risk group.

7 Jan 2021

Which strain should SARS-CoV-2 vaccine candidates target?

A researcher at Clemson University, USA, has recently explored how governments might effectively combat the pandemic through strategic vaccination as new variants and strains of the virus emerge. The study suggests that vaccine candidates should target the fast-spreading variant, even when the initial prevalence is much lower.

7 Jan 2021

Severe COVID-19 recovered patients do not display long-lasting adaptive immune responses, finds study

A team of scientists from the University of Valencia and INCLIVA Health Research Institute, Spain, has recently investigated the durability of immune responses specifically developed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19).

7 Jan 2021

Scientific experts help fight the spread of misinformation about COVID-19 vaccines

A team of renowned scientific experts has joined forces from across the world to help fight the spread of misinformation about the COVID-19 vaccines, which hold the key to beating the deadly pandemic and releasing countries from debilitating lockdown restrictions.

7 Jan 2021

Study: Durable immunity against secondary COVID-19 disease is possible in most individuals

Researchers who studied antibody and immune cell responses in more than 180 men and women who had recovered from COVID-19 report these patients' immune memory to the virus - across all immune cell types studied - was measurable for up to 8 months after symptoms appeared.

7 Jan 2021

Adaptive immune system against COVID-19 can last for at least eight months

New data suggest that nearly all COVID-19 survivors have the immune cells necessary to fight re-infection.

6 Jan 2021

Is one-dose COVID-19 vaccination better than two?

A recent study published on the preprint server medRxiv in December 2020 reflects on the possibility of using a single-dose vaccine regimen to accomplish large-scale vaccination as early as possible.

6 Jan 2021

In-silico modeling provides new understanding of immune response to SARS-CoV-2

The COVID-19 pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has crippled global healthcare systems and triggered an economic crisis in many countries. The pandemic is not showing signs of a slowdown even in 2021 with a new and more infectious variant of the virus wreaking havoc in the UK and many other parts of the world.

6 Jan 2021

Study shows durable specific humoral immunity against SARS-CoV-2 after mild or asymptomatic infection

As a part of the COMMUNITY (COVID-19 Immunity) study, researchers from Sweden reveal long-lasting IgG neutralizing antibody response against spike glycoprotein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the vast majority of convalescent individuals – even after asymptomatic or mild infection. Their results are currently available on medRxiv* preprint server.

6 Jan 2021